The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background
Open accessAbstract
Pheochromocytomas and paragangliomas (PCC/PGL) are tumors derived from the adrenal medulla or extra adrenal ganglia, respectively. They are rare and often benign tumors which are associated with high morbidity and mortality due to mass effect and high circulating catecholamines. Although most pheochromocytomas and paragangliomas are thought to be sporadic, over one third are associated with ten known susceptibility genes. Mutations in three genes causing well characterized tumor syndromes are associated with an increased risk of developing pheochromocytomas and paragangliomas including VHL (von Hippel-Lindau disease), NF1 (Neurofibromatosis Type 1), and RET (Multiple Endocrine Neoplasia Type 2). Mutations in any of the succinate dehydrogenase (SDH) complex subunit genes (SDHA, SDHB, SDHC, SDHD) can lead to pheochromocytomas and paragangliomas with variable penetrance, as can mutations in the subunit cofactor, SDHAF2. Recently, two additional genes have been identified, TMEM127 and MAX. Although these tumors are rare in the general population, occurring in 2–8 per million people, they are more commonly associated with an inherited mutation than any other cancer type. This review summarizes the known germline and somatic mutations leading to pheochromocytoma and paraganglioma development, as well as biochemical profiling for PCC/PGL and screening of mutation carriers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893 · cited 1×
“The penetrance for PCC/PGL in SDHD mutation carriers reaches 90% or higher by age 70 (50, 57).”
BackgroundMolecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
Min, J.-H., Yang, H., Ivan, M., Gertler, F., Kaelin, W. G., & Pavletich, N. P. (2002) · Science · doi:10.1126/science.1073440 · Cited by 765
Thompson, L. D. R. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200205000-00002 · Cited by 715 · cited 1×
“The histological PASS (Pheochromocytoma of the Adrenal gland Scaled Score) system is a graded score developed to help predict potential malignancy of adrenal based PCC, taking into account various histologic findings such as number of mitoses, amount of necrosis, and vascular density (3).”
BackgroundSDH5 , a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma
Hao, H.-X., Khalimonchuk, O., Schraders, M., Dephoure, N., Bayley, J.-P., Kunst, H., Devilee, P., Cremers, C. W. R. J., Schiffman, J. D., Bentz, B. G., et al. (2009) · Science · doi:10.1126/science.1175689 · Cited by 702 · cited 4×
“PGL2 (SDHAF2) The gene for PGL2 syndrome been identified as SDHAF2, also known as SDH5 (59).”
BackgroundInfluentialGuzy, R. D., Sharma, B., Bell, E., Chandel, N. S., & Schumacker, P. T. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01338-07 · Cited by 427
Vanharanta, S., Buchta, M., McWhinney, S. R., Virta, S. K., Peçzkowska, M., Morrison, C. D., Lehtonen, R., Januszewicz, A., Järvinen, H., Juhola, M., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/381054 · Cited by 389
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma
Qin, Y., Yao, L., King, E. E., Buddavarapu, K., Lenci, R. E., Chocron, E. S., Lechleiter, J. D., Sass, M., Aronin, N., Schiavi, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.533 · Cited by 379 · cited 4×
“The role it plays in cell signaling is still being determined, but evidence to date shows it is involved in the mTORC1 signaling pathway and co-localizes with the early endosome in the cell (96).”
BackgroundInfluential
Cited by
Pathogenic Germline Variants in 10,389 Adult Cancers
Huang, K.-L., Mashl, R. J., Wu, Y., Ritter, D. I., Wang, J., Oh, C., Paczkowska, M., Reynolds, S., Wyczalkowski, M. A., Oak, N., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.039 · Cited by 833
Gill, A. J., Hes, O., Papathomas, T., Šedivcová, M., Tan, P. H., Agaimy, A., Andresen, P. A., Kedziora, A., Clarkson, A., Toon, C. W., et al. (2014) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000292 · Cited by 347
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
Mitochondrial complex II, a novel target for anti-cancer agents
Kluckova, K., Bezawork-Geleta, A., Rohlena, J., Dong, L., & Neuzil, J. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.10.015 · Cited by 104
Metadata
- Authors
- Fishbein, L., & Nathanson, K. L.
- Venue
- Cancer Genetics
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 205
- Issue
- 1-2
- Pages
- 1-11
- ISSN
- 2210-7762 (ISSN-L)
- OpenAlex
- W2096795672
- Cited by
- 208
- References
- 15
- FWCI
- 21.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. https://app.cochat.ai/papers/10.1016/j.cancergen.2012.01.009
- The paper
- Fishbein, L., & Nathanson, K. L. (2012). Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genetics. https://doi.org/10.1016/j.cancergen.2012.01.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.